Several antipsychotic therapies are available for the treatment of schizophrenia and primarily control the positive symptoms of the disease. However, given that a sizable portion of schizophrenia patients do not respond adequately to current antipsychotics and that treatment is highly individualized, multiple drug development opportunities exist in this market. With the entry of newer long-acting depot atypical antipsychotics (e.g., Janssen’s Invega Trinza / Trevicta) and oral antipsychotics (e.g., Allergan / Gedeon Richter / Recordati’s Vraylar / Reagila), it is essential to understand how psychiatrists perceive the performance of current therapies and to determine the greatest areas of unmet need in this space. Moreover, with the anticipated availability of new therapies in the near future (e.g., Alkermes’s ALKS-3831), it is important to evaluate the remaining areas of opportunity in this market.
QUESTIONS ANSWERED
CONTENT HIGHLIGHTS
Geographies: United States, France, Germany, United Kingdom
Primary Research: Survey of 60 U.S. and 33 European psychiatrists
Key Drugs Covered: Invega Sustenna / Xeplion, Invega Trinza / Trevicta, paliperidone palmitate six-month depot, Rexulti / Rxulti, Vraylar / Reagila, ALKS-3831, lumateperone, pimavanserin, Abilify Maintena, aripiprazole, olanzapine, risperidone
Key Metrics Included:
PRODUCT DESCRIPTION
Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.